Phase 2a Study of HIV-1 Investigational Maturation Inhibitor
Bristol-Myers Squibb Company announced overall antiviral activity and safety results from the three-part Phase 2a proof-of-concept study of BMS-955176, a novel investigational therapy designed to prevent the maturation of HIV-1.The study findings support the continued development of BMS-955 ... more
Bristol-Myers Squibb appoints Paul Biondi Senior Vice President, Head of Business Development
Bristol-Myers Squibb Company announced that Paul Biondi has been appointed senior vice president, head of Business Development and will report to Charlie Bancroft, chief financial officer. In this role, Biondi will lead the development of strategic partnerships and pursue scientific innovat ... more
Bristol-Myers Squibb enters agreement to acquire Promedior, Inc.
Bristol-Myers Squibb Company and Promedior, Inc. announced that the companies have entered into an agreement that grants Bristol-Myers Squibb an exclusive right to acquire Promedior and gain worldwide rights to its lead asset PRM-151, a recombinant form of human pentraxin-2 protein in Phase ... more